We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?

This study has been completed.
Sponsor:
ClinicalTrials.gov Identifier:
NCT01159613
First Posted: July 9, 2010
Last Update Posted: July 9, 2010
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
Hillel Yafe MC Hadera
Information provided by:
Ziv Hospital
July 8, 2010
July 9, 2010
July 9, 2010
April 2008
October 2008   (Final data collection date for primary outcome measure)
sustained viral response [ Time Frame: 72 weeks ]
achieving SVR
Same as current
No Changes Posted
Not Provided
Not Provided
Not Provided
Not Provided
 
Do Low High Density Lipoprotein (HDL) Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?
Do Low HDL Levels Predict Treatment Outcome in Patients With Chronic Hepatitis C Viral Infection?
The working hypothesis is that the low HDL serum level predict favorable response to anti viral treatment in chronic HCV (genotype 1) viral infection. This might be used to improve the rate of sustained virologic response.

Lipoproteins are closely connected to the process of hepatitis C virus (HCV) infection. Metabolic syndrome predicts negative treatment outcome in HCV infection.

Aim: to assess the association between lipids components of the metabolic syndrome and sustained viral response (SVR).

Observational
Time Perspective: Prospective
Not Provided
Not Provided
Non-Probability Sample
chronic HCV genotype 1 naïve patients
Chronic Hepatitis C Viral Infection
  • Other: Responders
    Responders
  • Other: Non Responders
    Non Responders
  • Non Responders
    Non Responders
    Intervention: Other: Non Responders
  • RESPONDERS
    Intervention: Other: Responders
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
80
January 2009
October 2008   (Final data collection date for primary outcome measure)

Inclusion Criteria:

  • Chronic HCV genotype 1 naive patients

Exclusion Criteria:

  • Co infection with HBV, HIV, HDV
  • Decompensated liver disease
Sexes Eligible for Study: All
18 Years and older   (Adult, Senior)
No
Contact information is only displayed when the study is recruiting subjects
Israel
 
 
NCT01159613
HDL + HCV
Yes
Not Provided
Not Provided
Liver Clinic, Ziv medical center
Ziv Hospital
Hillel Yafe MC Hadera
Not Provided
Ziv Hospital
July 2010